Premium
Capecitabine for skin cancer prevention in solid organ transplant recipients
Author(s) -
Jirakulaporn Tanawat,
Endrizzi Bart,
Lindgren Bruce,
Mathew Josy,
Lee Peter K.,
Dudek Arkadiusz Z.
Publication year - 2010
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2010.01348.x
Subject(s) - medicine , capecitabine , discontinuation , basal cell carcinoma , mucositis , gastroenterology , incidence (geometry) , skin cancer , actinic keratosis , cumulative incidence , cancer , surgery , toxicity , transplantation , basal cell , physics , colorectal cancer , optics
Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients.
Clin Transplant 2011: 25: 541–548. © 2010 John Wiley & Sons A/S. Abstract: Skin cancers are the most common malignancies in solid organ transplant recipients (SOTR). A case‐observational, retrospective study was performed to determine the efficacy of low‐dose capecitabine in the secondary prevention of skin cancers in SOTRs treated at a single institution. SOTRs with recurrent squamous cell carcinoma (SCC) and/or basal cell carcinoma (BCC) were given low‐dose capecitabine 1 g/m 2 daily, days 1–14 of a 21‐d treatment cycle. Skin surveillance was performed by dermatologists every 1–3 months. Cumulative incidence rates of SCC, BCC, and actinic keratosis (AK) before and after treatment were scored and statistically compared for each patient using a non‐parametric Wilcoxon signed rank test. Fifteen patients (13 men and two women) with a median age of 57 yr (range 40–73) were treated. Incidence rates as measured by mean number of events per month declined by 0.33 for SCC, 0.04 for BCC, and 2.45 for AK (p < 0.05). The most common grade 3 and 4 toxicities included fatigue (40.0%), hand‐foot syndrome (20.0%), and diarrhea (20.0%). The discontinuation rate at one yr was approximately 33.3%. We conclude that oral capecitabine significantly decreases the incidence rates of recurrent SCC, BCC, and AK in SOTRs and is associated with manageable toxicity.